Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Blood Purif ; 36(2): 84-91, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23989183

RESUMO

BACKGROUND: Baxter received reports of visible precipitate, identified as calcium carbonate, forming during hemofiltration with Accusol 35 solution. AIM: To evaluate the potential for acute cardiopulmonary adverse effects of Accusol 35 containing exaggerated calcium carbonate particles. METHODS: Anesthetized dogs underwent continuous veno-venous hemofiltration (CVVH) with Accusol 35 containing visible and subvisible particles (≥10 µm) 36 times higher than the maximum concentration specified in the European Pharmacopoeia (P-Accusol), or Accusol 35 conforming to specification (Accusol). Select cardiovascular and blood gas parameters were evaluated during CVVH. Lung tissue samples were collected following CVVH. RESULTS: No differences were observed in cardiovascular and blood gas parameters or lung histology between P-Accusol and Accusol. CONCLUSION: Accusol 35 containing visible and subvisible particles (≥10 µm) 36 times higher than the maximum concentration specified in the European Pharmacopoeia resulted in no acute cardiopulmonary adverse effects compared with Accusol 35 containing no visible particles and subvisible particles within European Pharmacopoeia specification.


Assuntos
Carbonato de Cálcio/química , Traumatismos Cardíacos/etiologia , Soluções para Hemodiálise/efeitos adversos , Soluções para Hemodiálise/química , Hemofiltração/efeitos adversos , Hemofiltração/métodos , Lesão Pulmonar/etiologia , Animais , Cristalização , Cães , Concentração de Íons de Hidrogênio , Lesão Pulmonar/patologia , Masculino , Modelos Animais , Tamanho da Partícula
2.
Toxicol Pathol ; 39(5): 861-6, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21734251

RESUMO

Four groups of ten male and ten female rats each were treated intravenously with saline, 400 mg/kg/day of a commercially available injectable acetaminophen formulation, or 400 mg/kg/day of a new injectable acetaminophen formulation with (aged) or without (fresh) impurities daily for fourteen days. Gross observations of the mucosal surface of the stomachs from treated rats included multifocal to diffuse pale, elevated foci confined to the nonglandular region of the stomach. Treatment-related histologic observations consisted of epithelial hyperplasia and hyperkeratosis of the nonglandular mucosa of the stomach. The epithelial hyperplasia was characterized by a thickened epithelium, frequently accompanied by the development of undulations at the basement membrane zone, resulting in the formation of rete ridgelike structures protruding into the underlying tissue. The submucosa was usually expanded by edema and occasionally contained an infiltrate of neutrophils, eosinophils, and macrophages. The hyperplasia was usually accompanied by hyperkeratosis resulting in thickening of the stratum corneum. The incidence and severity of the gastric changes were similar across all treatment regimens. Although considered clinically irrelevant since humans do not have a forestomach equivalent, these results are significant in that this appears to be the first report of forestomach hyperplasia and hyperkeratosis following intravenous exposure to acetaminophen.


Assuntos
Acetaminofen/toxicidade , Mucosa Gástrica/efeitos dos fármacos , Gastropatias/induzido quimicamente , Acetaminofen/administração & dosagem , Analgésicos não Narcóticos/administração & dosagem , Analgésicos não Narcóticos/toxicidade , Animais , Peso Corporal/efeitos dos fármacos , Contaminação de Medicamentos , Feminino , Mucosa Gástrica/patologia , Histocitoquímica , Hiperplasia/patologia , Injeções Intravenosas , Masculino , Ratos , Baço/efeitos dos fármacos , Baço/patologia , Estômago/efeitos dos fármacos , Estômago/patologia , Gastropatias/patologia
3.
Nephrol Dial Transplant ; 26(10): 3349-57, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21398365

RESUMO

BACKGROUND: The high rate of cardiovascular mortality in patients with end-stage renal disease (ESRD) is a significant barrier to improved life expectancy. Unique in this population is the marked development and aggressive worsening of vascular calcification (VC). Pyrophosphate (PPi), an endogenous molecule, appears to naturally inhibit soft tissue calcification, but may be depressed in chronic kidney disease (CKD) and ESRD. Although once thought to be a promising therapeutic, PPi's very short half-life in circulation curtailed earlier studies. We tested the possibility that a slow, continuous entry of PPi into the circulation and prevention of VC might be achieved by daily peritoneal dialysis (PD). METHODS: Pharmacokinetic studies were first carried out in rats with renal impairment resulting from a 5/6 nephrectomy. Efficacy studies were then performed in the apolipoprotein E gene knockout mouse model overlaid with CKD. PPi was delivered by means of a permanent peritoneal catheter in a solution simulating PD, but without the timed removal of spent dialysate. von Kossa's staining followed by semiquantitative morphological image processing, with separation of inside (intimal) and outside (presumed medial) lesions, was used to determine aortic root calcification. RESULTS: In comparison to an intravenous bolus, delivery of PPi in a PD solution resulted in a slower, extended delivery over >4 h. Next, the efficacy studies showed that a 6-day/week PD-simulated administration of PPi resulted in a dose-dependent inhibition of aortic calcification in both intimal and medial lesions. A dose-response effect on total aortic calcification was also documented, with a full inhibition seen at the highest dose. A limited peritoneal catheter-related inflammation was observed, as expected, and included the placebo-treated control groups. This inflammatory response could have masked a lower level PPi-specific adverse effect, but none was observed. CONCLUSIONS: Our findings suggest potential for PPi, administered during PD, to prevent the development of VC and to potentially extend the life of ESRD patients.


Assuntos
Apolipoproteínas E/fisiologia , Soluções para Diálise/uso terapêutico , Difosfatos/administração & dosagem , Diálise Peritoneal/efeitos adversos , Insuficiência Renal/terapia , Calcificação Vascular/etiologia , Calcificação Vascular/prevenção & controle , Animais , Cálcio/metabolismo , Soluções para Diálise/farmacocinética , Difosfatos/farmacocinética , Feminino , Meia-Vida , Masculino , Camundongos , Camundongos Knockout , Ratos , Ratos Sprague-Dawley , Insuficiência Renal/complicações , Distribuição Tecidual , Uremia/tratamento farmacológico , Uremia/etiologia
4.
Anal Bioanal Chem ; 378(6): 1511-9, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15214411

RESUMO

Intact kidney tissue samples of normal and spontaneously hypertensive rats (SHRs) were analyzed by hrMAS-NMR spectroscopy and principal component analysis (PCA). Radial components (cortex, outer stripe of the outer medulla, inner stripe of the outer medulla, and papilla) were sampled from various regions across the kidney from multiple animals in order to establish inter- and intra-animal variability. The effects of temperature were also measured. Papilla was differentiated from the other tissue types, and this variation by tissue type was greater than the effect of temperature on the samples (spectra were compared from samples at 2 and 30 degrees C). This study also revealed long term stability issues of tissue storage at -80 degrees C. The PCA showed that the greatest differentiation between normal rats and SHRs was found in the cortex and the regions in the NMR spectra that were correlated with this variation were identified.


Assuntos
Hipertensão/metabolismo , Córtex Renal/metabolismo , Medula Renal/metabolismo , Rim/metabolismo , Ressonância Magnética Nuclear Biomolecular/métodos , Animais , Modelos Animais de Doenças , Técnicas In Vitro , Rim/química , Córtex Renal/química , Medula Renal/química , Masculino , Ratos , Ratos Endogâmicos SHR , Ratos Wistar , Temperatura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...